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Infection with the Tucson strain of coxsackievirus B1 (CVB1T) causes the development of chronic inflammatory myopathy
(CIM) and hind limb weakness in susceptible strains of mice. In this study, a panel of six plaque-purified viruses exhibiting
either small or large plaque phenotypes was derived from parental CVB1T and parental CVB1T that had been passaged
through monkey kidney cells. All six variants caused similar acute histopathology in muscle, but three of four passaged
viruses (AMP1, AMP2, and AMP3) did not induce CIM while the fourth (MP3) caused some hind limb weakness but without
associated muscle inflammation. In contrast, both viruses (MP1 and MP2) isolated directly from the parental CVB1T stock
were myopathic. Large plaque MP2 caused higher mortality and more rapid inhibition of host cell biosynthesis, but both
MP1 and MP2 induced CIM that was comparable to that induced by parental CVB1T . Plaque size was a stable characteristic
of the variants but did not correlate with their ability to induce CIM. Five of the six variants showed equivalent levels of
replication in muscle, monkey kidney cells, and G8 myoblasts while one, AMP3, was selectively impaired for replication.
Receptor binding and virus-induced inhibition of host cell transcription and translation were not linked to myopathogenicity.
Thus, most of the passaged variants are robust infectious viruses, suggesting that viral induction of CIM does not depend
solely on cytopathogenicity during the acute infection. q 1997 Academic Press
INTRODUCTION Manifestation of CIM appears to have a myopathic rather
than a neuropathic origin (Strongwater et al., 1984), and
In 1979 Ray et al. described a mouse model of chronic
mechanistic studies have shown that T cells are required
inflammatory myopathy (CIM) induced by infecting neo-
for development of CIM (Ytterberg et al., 1987; Ytterberg etnatal mice with the Tucson strain of coxsackievirus B1
al., 1988). This and the influence of the MHC on disease(CVB1T) (Ray et al., 1979). In this model, acute viral infec- severity point to a role for specific antigen recognition intion with associated muscle necrosis and inflammation
pathogenesis (Tam and Messner, 1996). Although the iden-lasts for about 2 weeks and is gradually supplanted by
tity of these antigens is unknown, responses to viral anti-a chronic inflammatory disease which persists in the
gens could be involved as viral RNA persists in muscleabsence of infectious virus. Chronic inflammation con-
and has been associated with development of CIM. Atsists of mononuclear cell (MNC) infiltration accompanied
1 month after infection, persistent viral RNA is evident inby ongoing myofiber degeneration and regeneration. The
degenerating myofibers that are surrounded by MNCs (Tamproximal hind limb muscle is primarily affected, and dis-
et al., 1991). Moreover, the kinetics of viral RNA persistenceease is clinically apparent as asymmetric hind limb
parallel the course of inflammation with both showing aweakness and a waddling gait. The histopathology of
gradual decay over the period of 1 to 6 months after infec-CIM resembles that of human polymyositis, making this
tion (Tam et al., 1994).a useful model of polymyositis specifically and of chronic
In their initial description of coxsackievirus-inducedpostviral inflammatory disease in general. Because of
CIM, Ray et al. (1979) compared the disease-causingtheir tropism for muscle, coxsackieviruses have long
potential of different field isolates of CVB1 to that of myo-been regarded as potential etiologic agents in diseases
pathic virus. Several of the field isolates caused littlesuch as the idiopathic inflammatory myopathies and
mortality or weakness whereas others were both virulentchronic fatigue syndrome, although evidence of their
and myopathic. Further study of virus-related differencesinvolvement is equivocal (Dalakas, 1992; Gow et al., 1991;
in disease induction have not been reported in thisLeff et al., 1992; Pachman et al., 1995; Swanink et al.,
model, although nonpathogenic variants of related vi-1994; Yousef et al., 1988).
ruses such as coxsackievirus B3 and Theiler’s virus have
been used to map changes in the viral genome that are
1 To whom correspondence and reprint requests should be ad- associated with development of myocarditis and chronicdressed at Department of Medicine, University of Minnesota Medical
demyelination, respectively (Chapman et al., 1994; Fu etSchool, Box 108 UMHC, 420 Delaware Street S.E., Minneapolis, MN
55455. Fax: (612) 624-0600. E-mail: tamxx001@maroon.tc.umn.edu. al., 1990; Stein et al., 1992). Some of these virus variants
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are defective and cause less mortality or show reduced natant. Litters were examined twice a day for 14 days to
evaluate morbidity and mortality due to the acute viralreplication in target tissue (Van Houten et al., 1991;
Zhang et al., 1993). However, being defective is not a infection. Except for the acute mortality study, mice exhib-
iting severe morbidity were euthanized by CO2 inhalation.prerequisite for loss of pathogenicity, and amyocarditic
variants of coxsackievirus B3 have been described Overt hind limb weakness was graded individually on a
scale of 0 to 3 as described previously with 0 indicatingwhose infectivity is equivalent to that of myocarditic virus
(Chapman et al., 1994; Gauntt et al., 1984). no weakness and 3 being the most severe grade of
weakness (Tam et al., 1991).To address the role of the virus in the induction of
CIM, we derived a panel of CVB1T variants by in vitro
Virus titerspassage of myopathic CVB1T . Passage selectively atten-
uated the ability of some variants to induce CIM without TCID50 assays were performed as previously de-
altering their ability to infect and replicate in muscle. For scribed (Tam and Messner, 1996). In brief, the tissue
the purposes of this paper, these variants are referred was removed aseptically, weighed, frozen, and stored at
to as amyopathic. Most of the amyopathic variants repli- 0707. Tissue to be assayed was thawed and disrupted
cated and caused acute muscle necrosis and inflamma- in DMEM using a ground glass homogenizer, insoluble
tion that were comparable to that caused by the parental debris was removed by centrifugation at 400 g, and 10-
virus. In addition, myopathic and amyopathic variants fold serial dilutions of the supernatant were prepared in
used the same cellular receptor and, following infection, DMEM. A 100-ml volume of BGMK cells and homogenate
caused equivalent downregulation of host cell transcrip- dilutions in DMEM-10 were added per well of a 96-well
tion and translation. Thus, virus-induced cytopathic ef- plate with six replicates for each dilution. Wells were
fects which occur during the acute infection are not scored for CPE (95% of cells rounded or dead) and the
solely responsible for subsequent development of CIM. 50% endpoint was used to calculate the TCID50 per gram
The panel of variants provides a genetically related group of tissue. Titers were determined by TCID50 assay instead
of type B1 coxsackieviruses that can be used to identify of the plaque assay because it was less biased for large
those virus-mediated events that are involved in the plaque viruses in which only a few plaques could be
pathogenesis of chronic postviral disease. reliably counted per plate and for small plaque viruses
for which some of the very small plaques were likely to
MATERIALS AND METHODS be overlooked.
Virus
Plaque assay
The parental stock of myopathic CVB1T originally ob- The virus plaque assay was performed as follows. Atained from S. Ytterberg was propagated by a single pas-
confluent monolayer of BGMK cells in a 100-mm petrisage through BGMK cells. When the cells exhibited
dish was overlaid with 800 ml of virus diluted in PBS. The95% cytopathic effect (CPE), virus-containing superna-
dish was incubated at 377 for 60 min after which thetants were prepared by two successive freeze–thaw cy-
supernatant was removed and replaced with 10 ml ofcles and centrifugation to remove cellular debris. Virus
agar overlay equilibrated to 507. The agar overlay con-stocks were titered by a 50% tissue culture infectious
sisted of 5% FBS and 0.9% Bacto-agar (Difco, Detroit, MI)dose (TCID50) assay and stored frozen at 0707. in MEM without phenol red. It was allowed to solidify at
room temperature and the dishes were then incubatedCells
for 5 days at 377 in 5% CO2 . To visualize plaques, 750 ml
Buffalo green monkey kidney (BGMK) cells were cul- of 0.16% neutral red in PBS was spread on top of the
tured in DMEM containing 1000 g/liter of glucose and agar and the dishes were reincubated for 1–5 hr. Plaque-
10% FBS (DMEM-10). G8 (ATCC, Bethesda, MD), a nontu- purified virus was recovered by stabbing into the agar
morigenic mouse myoblast cell line, was cultured in with a sterile pasteur pipette and transferring the agar
DMEM containing 4500 g/liter of glucose, 10% FBS, and plug to a tube containing 1 ml DMEM-10.
10% horse serum. BGMK and G8 cells were detached by
Production and selection of CVB1T variantstreatment with HBSS containing 0.05% trypsin and 0.02%
EDTA (Sigma, St. Louis, MO). BGMK cells were infected with parental CVB1T at ei-
ther a high (5.0) or a low (0.5) multiplicity of infectionMice
(m.o.i.). When the cells exhibited 95% CPE, the virus-
containing supernatant was harvested and used to infectPregnant CD-1 mice (Charles River Laboratories, Wil-
mington, MA) were used in all experiments. Mice were a fresh plate of BGMK cells, maintaining a high or low
m.o.i. through successive passages. After 30 passages,infected by intraperitoneal injection of virus within 48 hr
after birth. Uninfected control litters consisted of mice the high and low m.o.i. preparations were titered and
injected into mice to test for mortality and induction ofinjected with an equivalent dilution of BGMK cell super-
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CIM. Because it showed reduced myopathogenicity, the Northborough, MA). Over 99% of the virus was recovered
in the concentrate with an average of 0.06 cpm/virus. Tohigh m.o.i. virus preparation was plated to obtain
plaques, and those exhibiting either a small (£5 mm) or measure virus binding to the cellular receptor, target
cells were adjusted to 1 1 106/ml in HEPES-buffereda large (⁄10 mm) plaque phenotype were selected and
subjected to at least four additional rounds of plaque DMEM and transferred in 100-ml amounts to 1.5-ml sili-
conized microfuge tubes. Radiolabeled virus (2 1 105purification to maximize homogeneity of the plaque phe-
notype. Virus variant stocks were produced from a single virus in 500 ml DMEM) was added, and the tubes were
mixed with gentle rocking for 90 min at room tempera-passage of this plaque-purified virus through BGMK
cells. CVB1T variants were designated as myopathic (MP) ture. The cells were pelleted by centrifugation and
washed twice with a 1-ml volume of PBS. After the sec-or amyopathic (AMP) based on their induction of chronic
disease. Myopathic variants were defined as those ond wash the cell pellet was solubilized in 50 ml of 5%
SDS and transferred to a scintillation vial. The quantitywhich caused detectable hind limb weakness or muscle
inflammation characterized by MNC infiltrates at 28 days of bound virus was determined by liquid scintillation
counting. For experiments in which monoclonal antibodyafter infection while amyopathic variants did not cause
any sign of either chronic weakness or CIM. 10A1 (Weller et al., 1989) (provided by Dr. Sally A. Huber)
was used to block virus binding, the antibody was pre-
Histology pared by ammonium sulfate precipitation from ascites,
and the protein concentration was determined by Coo-Mice were anesthetized with ether and killed by cervi-
massie dye binding (Bio-Rad, Hercules, CA). Ascites pro-cal dislocation. A transverse section from the center of
duced by myeloma P3X63-Ag8.653 (P3) was processedthe hamstring muscle was excised and positioned to
in parallel and used to control for nonspecific blocking.obtain cross sections by mounting it on a cork coated
To measure the effect on virus binding, antibody waswith a thin layer of Tragacanth gum. The muscle was
preincubated with the target cells for 30 min at roomfrozen in liquid nitrogen-cooled isopentane, transferred
temperature before radiolabeled virus was added. Com-to coded cryotubes, and stored at 0707. Sections were
petitive binding studies were performed by mixing thecut at a thickness of 5 mm in a cryostat and adhered to
unlabeled blocking virus with radiolabeled virus beforeslides coated with Histogrip (Zymed, San Francisco, CA).
adding the mixture to BGMK cells.Muscle sections were stored at 0207. Pathology was
evaluated on slides stained with Gomori trichrome and
[3H]Uridine and [3H]leucine incorporationhematoxylin and eosin (Engel and Cunningham, 1963).
by host cells
One-step growth curves Host cells were plated at 2 1 104 cells per well in a
96-well culture plate and incubated overnight (18 hr). TheHost cells were plated at 2 1 105/ml in 24-well culture
cells were then infected with 8 1 105 TCID50 of virus andplates. The cell monolayer was washed three times with
incubated for various times as indicated. Two hours prior2 ml PBS and 4 1 106 virus was added in 0.5 ml of
to harvest, 2 mCi of L-[3,4,5-3H(N)-leucine (180 Ci/mmol)DMEM. Virus was allowed to attach for 60 min at room
(DuPont NEN, Wilmington, DE) or 1 mCi of [5,6-3H]uridinetemperature, after which the monolayer was washed
(35 Ci/mmol) (ICN Pharmaceuticals, Irvine, CA) wasthree times with 2 ml PBS to remove unattached virus.
added. To determine radioisotope incorporation, macro-Immediately after 2 ml of DMEM-10 prewarmed to 377
molecules were harvested onto glass filters using a PHDwas added, a Time 0 sample was taken and the plate
cell harvester (Cambridge Technology, Watertown, MA)was incubated at 377 in 5% CO2 . Cell supernatants were
and quantified by liquid scintillation counting.sampled at various times after infection and stored at
0707 until the virus was titered by TCID50 assay.
RESULTS
Virus receptor binding
Myopathogenicity of passaged CVB1T
Binding to the viral receptor was measured using 35S-
labeled virus prepared as follows. A monolayer of 2 1 Mice were infected with the parental stock of CVB1T
or parental CVB1T that had been subjected to 30 pas-10
7 BGMK cells was infected with 2 1 108 virus for 1 hr
at 377. Infected BGMK cells were then washed twice with sages in BGMK cells at either a high or a low m.o.i. Titers
of the high and low m.o.i. populations were similar afterPBS and incubated in methionine-free MEM at 377 for 30
min followed by the addition of 500 mCi [35S]methionine passage with the low m.o.i. CVB1T at 9.0 1 106 TCID50/
ml and the high m.o.i. CVB1T at 3.8 1 106 TCID50/ml.(Amersham, Arlington Heights, IL). After 24 hr the cells
exhibited95% CPE and the cell-free supernatants were When these viruses were inoculated into mice they repli-
cated to a similar degree in muscle, and the acute titersharvested as described above. Unincorporated radioac-
tivity was removed by centrifugal diafiltration using a corresponded to the quantity of virus that was injected
(Table 1). Parental CVB1T and low m.o.i. CVB1T showedmembrane with a 50K cutoff (Macrosep 50, Pall Filtron,
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TABLE 1
Effects of Passage through BGMK Cells on CVB1T Replication, Acute Mortality, and Induction of Hind Limb Weakness
Acute Percentagea of hind limbs at weakness grade
CVB1T No. TCID50 Virus titer (log mortality
preparation injected TCID50/g muscle) (%) 0 1 2 3
Parental 100 7.1 3/17 (18) 11 57 25 7
400 7.8 8/24 (33) 19 47 22 12
Low m.o.i. 100 6.9 12/25 (48) 23 46 19 12
400 8.6 10/12 (83) 25 0 50 25
High m.o.i. 100 7.1 5/19 (26) 68 14 11 7
400 8.1 1/9 (11) 56 31 6 6
a Hind limbs were graded for increasing severity of weakness on a scale of 0 to 3 as described under Materials and Methods.
higher rates of mortality upon increasing the inoculum the inoculated virus. This held true even for the large
plaque variants which had initially constituted a minorityfrom 100 to 400 TCID50 , whereas the high m.o.i. CVB1T
was unaffected. Those mice that survived infection with (2–9%) of the parental, low m.o.i., and high m.o.i. popula-
tions of virus (data not shown).the high m.o.i. CVB1T had a reduced incidence and sever-
ity of chronic hind limb weakness following infection (x2
Myopathogenicity of CVB1T variantstest of association for the 100 TCID50 dose; P  0.0001),
suggesting that this virus was less myopathic than either Variants were considered to be amyopathic if infected
the parental or the low m.o.i. virus. In subsequent experi- mice lacked any sign of chronic hind limb weakness or
ments, viruses were plaque-purified from the high m.o.i. inflammation at 4 weeks after infection. Of the six variants
preparation in an attempt to isolate variants with reduced tested, three were myopathic (MP1, MP2, and MP3) and
myopathogenicity. three were amyopathic (AMP1, AMP2, and AMP3) (Table
3). Myopathogenicity did not correlate with plaque sizeDerivation and virulence of CVB1T variants as both small and large plaque variants were obtained
Both parental CVB1T and the high m.o.i. virus prepara- that expressed either a myopathic or an amyopathic phe-
tion were plated to yield plaques, and individual plaques notype. On the other hand, three variants (AMP1, AMP2,
were then selected for further study according to their and AMP3) from the high m.o.i. preparation were com-
size. Small plaque (£5 mm) and large plaque (⁄10 mm) pletely attenuated for myopathogenicity with the fourth
viruses were sequentially replated four to five times to variant (MP3) causing visible hind limb weakness but
achieve maximum homogeneity of the plaque phenotype. without associated muscle inflammation. x2 analysis in-
The viruses that were examined in greater detail included dicated that the distribution of weakness severity in vari-
one each of the small and large plaque viruses derived ants MP1 and MP2 did not differ from that caused by
from the parental CVB1T population, and two each of the
small and large plaque viruses derived from the high
TABLE 2m.o.i. CVB1T population (Table 2). The six plaque-purified
variants were inoculated into mice at 100 TCID50/mouse Plaque Phenotype and Mortality of CVB1T Variants
in parallel with the parental CVB1T as a positive control
Plaque Acuteand uninfected BGMK cell supernatant as a negative
Number of Plaquea phenotypeb mortalitycontrol. Five of the six variants showed levels of acute
CVB1T passages phenotype recovery No. dead/totalmortality that were similar to that of parental CVB1T (Ta- variant in BGMK (%) (%) (%)
ble 2) with most of the deaths occurring on Days 4
Parental 0 Small (91) 97 32/98 (33)through 10 (Fig. 1). The exception was MP2, a large
MP1 0 Small (97) 98 22/74 (30)plaque virus derived from parental CVB1T , which was
MP2 0 Large (100) 99 34/36 (94)more virulent and caused 94% mortality. In subsequent
MP3 30 Large (98) 94 7/32 (22)
studies on chronic disease induction in survivors the AMP1 30 Small (98) 100 6/29 (21)
dose of MP2 was reduced to 10 TCID50/mouse, decreas- AMP2 30 Small (97) 98 13/55 (24)
AMP3 30 Large (100) 96 14/51 (27)ing the overall mortality to 54% (data not shown). Plaque
phenotype was a stable characteristic for all variants,
a Plaque size of the inoculated virus was classified as small (£5even after replication in vivo. The plaque phenotype of
mm) or large (⁄10 mm) and is expressed as a percentage of the total
variants used for inoculation was at least 97% homoge- plaques.
neous and, at 7 days after infection, 94% or more of the b Percentage of plaques recovered from muscle at 7 days after infec-
tion that had the same size phenotype as the virus that was inoculated.virus recovered from muscle retained the phenotype of
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response at 7 days after infection as illustrated by the
examples of AMP2 and AMP3 shown in Fig. 2. It should
be noted that parental CVB1T , MP2, and AMP1 showed
similar levels of myofiber destruction and inflammation
at 7 days (histology not shown). At 28 days, noninflamma-
tory sequelae of infection were induced by both myo-
pathic and, at a slightly lower frequency, amyopathic vari-
ants. These included variations in myofiber size and
shape and myofiber regeneration as indicated by central-
ized nuclei.
Growth characteristics
Growth capacity of the CVB1T variants was examined
to determine whether pathogenetic differences resulted
from primary defects in viral infection and replication.
Over the course of acute infection, muscle titers of myo-
pathic variants were comparable to those of parentalFIG. 1. Acute mortality of mice infected with CVB1T variants. Mice
CVB1T (Fig. 3). AMP1 behaved similarly, but the otherwere injected with 100 TCID50 of parental CVB1T , one of six CVB1T
variants, or BGMK cell supernatant diluted in PBS (uninfected control) amyopathic variants differed. Most notably, AMP3
on Day 0. Acute mortality was evaluated daily. The cumulative percent- showed a slightly reduced peak titer at 5 days and was
age mortality and numbers of mice in each group are presented in more rapidly eliminated from the muscle while AMP2Table 2.
infection was prolonged with half of the mice tested still
harboring infectious virus at 14 days. Persistence of
AMP2 infection was not maintained, as virus was notthe parental CVB1T , whereas for MP3 the severity was
significantly reduced (P  0.05). Thus, both variants that recovered from any of six mice tested at 21 days (data not
shown). Thus, of the AMP variants, only AMP3 showed awere derived directly from the parental stock of CVB1T
caused weakness and CIM that were indistinguishable significant decrease in titer that could have been due to
either reduced replication or enhanced clearance fromfrom this stock. The MNC infiltrates and myofiber calcifi-
cation typical of CIM were not observed in mice infected muscle. To evaluate differences in tropism, virus titers
were also measured in the kidney at 5 days after infec-with either MP3 or any of the three AMP variants (Table
3 and Fig. 2). Also, CIM could not be induced by increas- tion. In general, titers were 100–1000 times lower than
in muscle as follows: MP1 (5.3 TCID50/g); MP2 (6.1ing the inoculum of these variants to 400 TCID50 (data
not shown). Lack of CIM development occurred despite TCID50/g); MP3 (4.9 TCID50/g); AMP1 (5.3 TCID50/g);
AMP2 (4.5 TCID50/g); AMP3 (5.7 TCID50/g). Although com-the presence of an equally vigorous acute inflammatory
TABLE 3
Chronic Hind Limb Weakness and Muscle Pathology in Mice Infected with CVB1T Variants
Percentagea of hind limbs Histopathology b
at weakness grade
CVB1T MNC Myofiber Myofiber size/shape Centralized
variant 0 1 2 3 infiltrates calcification variations myofiber nuclei
Parental 23 39 28 11 3 { 2 7 { 5 5/5 5/5
MP1 28 43 20 9 3 { 1 5 { 4 5/5 5/5
MP2 11 42 30 17 2 { 1 8 { 4 5/5 5/5
MP3 46 28 20 6 0 0.4 { 0.3 5/5 5/5
AMP1 100 0 0 0 0 0 3/5 5/5
AMP2 100 0 0 0 0 0 4/5 5/5
AMP3 100 0 0 0 0 0 3/5 5/5
a Hind limb weakness was evaluated for both the right and left hind limb from the following numbers of animals: parental, N  66; MP1, N 
52; MP2, N  18; MP3, N  25; AMP1, N  23; AMP2, N  42; AMP3, N  37.
b Histopathology was evaluated by examination of 10 randomly chosen microscopic fields (magnification 1100) on each of 5 sequential sections
cut from the right hamstring muscle. Five mice were examined for each CVB1T variant. For MNC infiltrates and myofiber calcification, numbers
represent the mean number of foci and number of calcified myofibers, respectively, per section { 2 SEM. Observed variations in myofiber size or
shape and the presence of centralized nuclei are presented as the number of mice in which this feature was observed out of a total of 5 mice
examined.
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FIG. 2. Histopathology of acute and chronic CVB1T-induced myositis. Hamstring muscle was harvested on Day 7 (A, C, E, and G) or Day 28 (B,
D, F, and H) to evaluate the development of acute and chronic myositis, respectively. The histology of uninfected muscle (A and B) is shown for
comparison with that of mice injected with MP1 (C and D), AMP2 (E and F), or AMP3 (G and H). At the peak of acute infection at 7 days, mice
infected with all three virus variants show widespread myofiber destruction and infiltration of inflammatory cells. By 28 days, muscle infected with
AMP2 and AMP3 had regenerated whereas muscle infected with MP1 showed typical CIM development consisting of focal MNC infiltrates, myofiber
calcification (dark staining necrotic fibers), and fatty replacement (hematoxylin and eosin staining, original magnification 1100).
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Cellular receptor binding
The possibility that amyopathic and myopathic variants
bind to different receptors was explored using two differ-
ent approaches. One was to use a monoclonal antibody
which binds to the CVB receptor to inhibit the binding of
radiolabeled virus to BGMK and G8 cells (Weller et al.,
1989). Because several different molecules have been
described as potential CVB receptors (Bergelson et al.,
1995; de Verdugo et al., 1995; Mapoles et al., 1985), com-
petitive binding between radiolabeled and unlabeled vi-
rus was also examined. Two variants, MP1 and AMP3,
were used as radiolabeled indicators. A preliminary ex-
periment compared the binding of MP1 and AMP3 to
BGMK and G8 cells over a 4-hr period at 30-min intervals
and revealed that they bound at similar rates with satura-
tion after 2 hr (data not shown). In the first set of blocking
experiments, mAb 10A1 reduced the binding of both MP1
and AMP3 to BGMK and G8 cells in an equivalent, con-
centration-dependent manner (Fig. 5). In the second set
of experiments, AMP3 effectively blocked the binding of
MP1 and, in the reciprocal experiment, MP1 showed
equivalent blocking of AMP3 binding (Fig. 6). Moreover,
all of the remaining variants (MP2, MP3, AMP1, and
AMP2) were able to block the binding of either MP1 or
AMP3. Radiolabeled viruses were blocked as effectively
by other variants as they were by themselves. Taken
together, both sets of experiments suggest that all of
the myopathic and amyopathic variants use a common
cellular receptor.
FIG. 3. Acute virus titers in proximal hind limb muscle. Markers
Inhibition of host cell transcription and translationrepresent the mean of titers in hamstring muscles from at least three
mice. Cases in which virus was below detectable levels for some mice
The ability to shut down host cell transcription andare indicated by asterisks and the mean is given only for those with
translation was compared at 2-hr intervals over a 6-hra measurable titer. Virus-negative mice included three of six mice nega-
tive for AMP2 at 14 days and three of six mice negative for AMP3 at period following infection of BGMK and G8 cells (Fig.
7 days. The lower limit of detection is indicated by the dotted line at 7). Inhibition of host cell macromolecular synthesis was
70 TCID50/g muscle. evident after 2 hr and only one variant, MP2, showed
enhanced inhibition, especially in G8 myoblasts. The re-
promised in the muscle, AMP3 replicated as well as other maining variants reduced cellular metabolism with simi-
variants in the kidney. In addition, MP2 showed the high- lar kinetics and to an equivalent degree without any ap-
est kidney titer among all the variants, which could be parent G8 myoblast-specific differences.
responsible for its greater lethality.
One-step growth curves of virus in BGMK or G8 cells DISCUSSION
were used to evaluate viral replication without interfer-
In vitro passage at a high m.o.i. has traditionally beenence from the host immune response. In general, growth
used to generate attenuated variants of picornaviruses.kinetics of virus were slightly more rapid in BGMK than
Such variants often show reduced tropism for the particu-in G8 myoblasts, although the final peak titers were simi-
lar target tissue involved in disease expression. It waslar (Fig. 4). Again, AMP3 was the only variant whose
therefore unexpected that three of the four passagedreplication was compromised, and this effect was much
variants (AMP1, AMP2, and MP3) described in this reportmore pronounced in G8 cells. Thus, growth in muscle in
were attenuated for development of the chronic phasevivo or in G8 myoblasts in vitro was not impaired in
of muscle disease without a concomitant reduction inany of the three myopathic variants or in two of three
acute infectivity or growth in muscle. Replication wasamyopathic variants. On the other hand, the amyopathic
robust and accompanied by extensive necrosis and in-phenotype of AMP3 could have been due largely to a
flammation that were comparable to that caused by vari-defect that specifically restricted replication in muscle
cells. ants MP1 and MP2 isolated from the parental stock of
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FIG. 4. One-step growth curves of CVB1T variants in BGMK and G8 cells compared to growth of parental CVB1T . Virus was added to cell
monolayers at an m.o.i. of 20 and allowed to attach at room temperature for 60 min. Unattached virus was removed by washing and the monolayers
were incubated in complete medium at 377. Virus released into the supernatant was titered by TCID50 at the indicated times.
CVB1T . By 4 weeks after infection this picture had by higher levels of mortality and enhanced shut-down of
host cell biosynthesis. Increased lethality of MP2 mightchanged dramatically, with typical manifestations of CIM
in mice infected with MP1 or MP2 but not the passaged also be linked to greater replication in essential organs
such as the kidney. Despite these differences, both MP1variants. This signifies that acute muscle damage alone
was not sufficient to precipitate development of chronic and MP2 replicated in muscle and caused CIM, unlike
studies of coxsackievirus B4 in which only the largedisease, which must be induced by other factors linked
to infection with the myopathic variants. Our previous plaque variant is pancreatropic and causes disease
(Ramsingh et al., 1995). No differences were exclusivelystudies on inbred strains have shown that CIM develop-
ment is multigenic with the MHC region influencing the associated with plaque size of the passaged attenuated
CVB1T variants. Similarly, both large and small plaqueseverity of CIM in susceptible mice and other non-MHC
background genes conferring resistance (Tam and attenuated variants have been described for coxsackie-
virus B3 (Zhang et al., 1994; Zhang et al., 1993). Thus,Messner, 1996). It is therefore possible that AMP variants
lack appropriate viral antigens for presentation to T cells relationships between plaque size and pathogenicity
were not absolute but may be indicative of certain char-or may not stimulate production of certain proinflamma-
tory molecules that lead to development of CIM. acteristics when comparing highly related variants, such
as MP1 and MP2, that were derived directly from thePlaque size was used as an indicator to select viruses
with potentially different growth characteristics and parental CVB1T population.
AMP3 was the only variant whose replication was clearlypathogenicity. Little reversion of the plaque size pheno-
type was observed during in vivo growth, indicating that impaired. This defect was manifest selectively in muscle
but not in the kidney where levels of virus were comparableit was a stable characteristic of each variant. For variants
derived directly from parental CVB1T , large plaque MP2 to those of other variants. Reduced titers in muscle were
most likely due to an inherent defect in the replicative abilitywas more virulent than small plaque MP1 as evidenced
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Although differences in receptor usage have been
linked to disease induction in other models of virus-in-
duced autoimmunity (Eaton, 1980; Van Houten et al.,
1991), all of the CVB1T variants bound to the same cellu-
lar receptor regardless of their myopathogenicity. In con-
trast, immune responses to the coxsackievirus B3 recep-
tor directly contribute to the pathology of myocarditis
(Weller et al., 1989), and an antibody 10A1 escape variant
of this virus not only uses an alternate receptor but is
attenuated for induction of myocarditis (Van Houten et
al., 1991). Although we cannot rule out the possibility that
a CVB1T variant specifically selected for its use of an
alternate receptor might likewise be amyopathic, the
CVB1T variants demonstrate that altered receptor usage
is not a prerequisite for reduced myopathogenicity. Even
if anti-receptor responses are involved, there must be
other auxiliary events which contribute to CIM develop-
ment. Common receptor usage also makes it less likely
that myopathogenicity arises by preferential infection of
FIG. 5. Antibody 10A1-mediated blocking of radiolabeled MP1 or
AMP3 binding to the virus receptor on BGMK and G8 cells. Antibody
was preincubated with the target cells for 30 min prior to the addition of
radiolabeled virus. Monoclonal antibody 10A1 binds to a coxsackievirus
receptor while P3 is a negative control antibody preparation. Values
are the mean of triplicate samples.
of AMP3 rather than enhanced immune clearance, as in
vitro replication was also impaired. Despite reduced viral
replication, significant muscle damage occurred during the
acute infection, and histopathology after 7 days was com-
parable to that of the parental variants. Other aspects of
AMP3 infectivity were also unchanged. Both AMP3 and
MP1 bound to the same cellular receptor as shown by
blocking with the anti-CVB receptor antibody 10A1 and by
competitive binding experiments. Moreover, both variants
reduced macromolecular synthesis in BGMK and G8 cells
with similar kinetics and to a similar degree. Thus, defective
replication of AMP3 in muscle does not appear to be linked
to altered virus binding or defective shut off of host cell
metabolism. This suggests that early events in AMP3 infec-
FIG. 6. Competitive binding of CVB1T variants to the viral receptor ontion are normal but that the later steps in viral replication
BGMK cells. Radiolabeled MP1 or AMP3 was mixed with the indicatedor assembly are compromised. The selectivity of this defect
amount of unlabeled variant, added to BGMK cells, and incubated for
for muscle indicates that AMP3 may have developed an 90 min at room temperature. As a negative control, binding of radiola-
added dependence on a host factor present at sufficient beled virus was evaluated in the presence of an equivalent amount of
supernatant from uninfected BGMK cells.levels in BGMK but not muscle cells (Andino et al., 1990).
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FIG. 7. Inhibition of BGMK and G8 muscle cell metabolism following viral infection. Cells were infected at time 0 and evaluated at 2, 4, and 6 hr
after infection. 3[H]Uridine or 3[H]leucine was added at 2 hr prior to cell harvest. Data are the mean of three replicates, and one of two experiments
is shown.
different types of cells, for example, cells of the immune and no muscle cell-specific differences were observed.
Thus, we have produced several CVB1T variants thatsystem. Klingel et al. (1996) found persistent CVB3 RNA
in splenic B cells whereas we have detected persistent show normal tropism for muscle but do not induce the
later development of CIM. Given the prevalence of cox-CVB1T RNA in skeletal muscle, heart, and brain but not
in the spleen (Tam et al., 1994). Also, CVB1T is rarely sackievirus infections in the general population (Pal-
lansch, 1988) and hypotheses regarding their role in therecovered from the spleen during acute infection and we
have been unable to productively infect lymphocytes or less common chronic muscle diseases, it is possible
that a minority of these infections actually combine themacrophages in vitro (unpublished observations), mak-
ing it less likely that there are effects mediated by direct conditions of host susceptibility and myopathic virus that
are required for chronic disease development. Althoughinfection of immune system cells.
Effects of viral infection on host cells include interfer- viral factors that govern CIM development have not been
identified in the mouse model, pathogenesis of CIM ap-ence with normal host cell metabolism, which may influ-
ence pathogenesis (Oldstone et al., 1984). However, all parently depends more on specific interactions between
the virus and the host immune system than cytopathoge-the amyopathic CVB1T variants showed inhibition of host
cell transcription and translation that was remarkably nicity and growth during the acute infection. The key
to understanding pathogenesis of CIM may lie in theequivalent to that of MP1. This included AMP3 whose
own replication was restricted in BGMK and G8 cells. presentation of appropriate antigens, stimulation of pro-
inflammatory cytokines, or one of the many other pertur-Inhibition was initiated with the same kinetics which,
taken together with the previously discussed data, sug- bations of the immune system that could be initiated
during the viral infection. Mapping of viral genomic re-gest that the entire process of viral attachment, entry, and
replication was not altered for most of the amyopathic gions that differ between myopathic and amyopathic vari-
ants will direct the course of future experiments to iden-variants. Both BGMK and G8 muscle cells were affected,
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(1984). Viral perturbation of endocrine function: Disordered cell func-tify virus-specific events that are linked to CIM develop-
tion leads to disturbed homeostasis and disease. Nature (London)ment.
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